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This paper reviews current screening techniques as well as novel biomarkers and their potential role in early detection of ovarian
cancer. Ovarian cancer is one of the most common reproductive cancers and has the highest mortality rate amongst gynecologic
cancers. Because most ovarian cancer diagnoses occur in the late stages of the disease, ﬁve-year survival rates fall below 20%.
To improve survival rates and to lower mortality rates for ovarian cancer, improved detection at early stages of the disease is
needed. Current screening approaches includetumormarkers,ultrasound,oracombination.Eﬀorts areunderwayto discovernew
biomarkersofovariancancer in order to surmounttheobstacles inearly-stage diagnosis.Amongserum protein markers,HE4 and
mesothelincanaugmentCA125detection providinghighersensitivityandspeciﬁcity duetothepresence oftheseproteins inearly-
stageovarian cancer. Detection testing that includes methylation of the MCJ gene and increased expression of vascular endothelial
growth factor is correlated to poor prognosis and may predict patient survival outcome. Detection testing of biomarkers with
long-term stability and combination panels of markers, will likely lead to eﬀective screening strategies with high speciﬁcity and
sensitivity for early detection of ovarian cancer.
1.Introduction
Despite the development of new treatments and therapies
designed to improve the ﬁve-year survival rate, ovarian
cancer still remains the deadliest cancer of the female
reproductive tract [1]. Due to the 21,550 new cases and
14,600 deaths estimated by the National Cancer Institute
in 2009, it also continues to be the ﬁfth leading cause of
cancer death in women throughout the United States [2].
Unfortunately, most cases are diagnosed in the late stages
of the disease, when the ﬁve-year survival rates fall below
20%. Actually, less than 25% of cases are limited to the ovary
alone at the time of diagnosis [3], with most patients having
metastatic disease at presentation. This further contributes
toworsening theprognosis. The lack of precise early warning
s i g n si so n eo ft h ef a c t o r st h a tf u r t h e rc o n t r i b u t et ot h ef a c t
that only 25% of ovarian tumors are identiﬁed at stage I
[4]. As most cases present in late stages of the disease, few
opportunities are present for treatment and to ultimately
improve survival.
Many risk factors have been associated with the increas-
ing prevalence of ovarian cancer; these include age (mainly
perimenopausal and postmenopausal age), positive family
history (5–10% of cases are familial) [5], genetics (BRCA1
and BRCA2 oncogenes), diet (mainly meats and saturated
fats) [1], and other reproductive factors. Factors that have
been shown to decrease the risk consist of oral contra-
ceptive use, increasing parity, and gynecological surgeries
(hysterectomies and tubal ligation) [1, 6–8]. Other elements
such as breast feeding and the use of hormone replacement
therapy (HRT) have demonstrated little or no eﬀect on risk
[1, 6].2 Journal of Oncology
2.Methods
A comprehensive literature review was performed in
PubMedusingthekeywords“ovarian cancer”and“biomark-
ers.” The results produced were ﬁltered by limiting the search
to manuscripts which discussed studies of human subjects
within the past ten years. This initial search produced 4,400
associated papers. Additional searches were further per-
formed using the keywords cancer, cancer of female gonad,
genetic markers, molecular markers, diagnostic markers,
and prognostic markers to supplement the information that
was obtained. 48 papers were selected for inclusion in the
manuscript following careful review of the abstracts. These
papers consisted of 1 meta-analysis, 10 reviews, and 37
original papers.
Subsequent searches were also performed in the gyneco-
logical book, Ovarian Cancer: Methods and Protocols,u s i n g
the same keywords as utilized in the PubMed database.
Following thorough review of the introductions (as no
abstracts were available), 3 additional review papers were
selected for inclusion in the manuscript.
3.Diagnostic ProceduresinOvarianCancer
Despite these setbacks, early diagnosis of ovarian cancer
has shown to improve the ﬁve-year survival rates to over
90%. Detection at early stage oﬀers a potential reduction in
mortality. Massive eﬀorts have been devoted to discovering
an eﬀective screening mechanism for early-stage diagnosis
prior to the onset of clinical symptoms.
The objective of such a screening mechanism revolves
around reducing mortality with an early-stage diagnosis.
Currently, diagnosis of early stages of the disease is very
limited, as there have been no clinically accepted tests or
screening mechanisms approved for this purpose. The focus
and interest of many researchers and clinicians has been
drawn upon many novel diagnostic markers that may be
present within early-stage ovarian tumors, as many marker
panels have shown promise recently [9]. There are many
challenges that prevent utilizing biomarkers as a potential
screening tool. The preeminent screening methods have
focused on detecting cancer before it becomes invasive
through the identiﬁcation of precursor lesions. This allows
for the prevention of invasive ovarian cancer through early-
intervention techniques. This paper will focus on current
screening techniques, as well as novel biomarkers and their
potential role in early detection of ovarian cancer.
3.1. Current Screening Techniques and Limitations in the
Early Diagnosis of Ovarian Cancer and Tumor Markers as
a Screening Modality. Existing screening modalities have
been classiﬁed according to the ﬁrst-line test. The screening
approaches utilized across a large population base have
centered on the use of tumor markers, ultrasound (com-
monly transvaginal ultrasound), or a combination of both
techniques [10, 11]. Secondary tests usually follow ﬁrst-
line tests, on the basis of a positive or equivocal result.
Applied to a smaller population base, the secondary test
is typically color Doppler ultrasound if the ﬁrst-line tests
are tumor markers or vice versa [11]. Both tumor markers
and ultrasound have various advantages and disadvantages
that determine their ultimate eﬀectiveness in screening for
early-stage ovarian cancer. Utilized for multiple purposes in
clinical practice such as screening asymptomatic patients,
treatment planning, and disease recurrence monitoring,
tumor markers have shown great promise as being mostly
inexpensive, noninvasive, and with relatively fast processing
times. Numerous markers can also bedetectedin the plasma,
serum, peritoneal ﬂuid, or in the urine.
Despite their many practical uses, tumor markers have
not obtained widespread acceptance for early detection of
disease, as few markers have shown potential in overcoming
the many challenges of a screening modality to enter
randomized control trials [11]. Natural biological variation
of certain markers may occur over time, creating a number
of false-positive results. Assay measurement error may also
occur [11]. Additionally, with the high costs that accompany
large randomized controlled trials and the relatively low
occurrence of most cancers, only the most promising
markers have been evaluated further. Cancer antigen 125
(CA125) has shown to be one of those markers.
3.1.1. Cancer Antigen 125. Currently, the only biomarker
that has proven to detect ovarian cancer before the onset
of clinical symptoms and is widely used in clinical practice
is CA125 [3]. As a high-molecular-weight glycoprotein,
CA125 is normally expressed in a variety of epithelial
cell types. These range throughout adult tissues derived
from Mullerian (endocervical, endometrial, and tubal) and
coelomic (peritoneum, pericardium, and mesothelial cells of
the pleura) epithelia [12]. CA125 is reported to have one
of the highest sensitivity and speciﬁcity among biomarkers
for ovarian cancer. Nakae et al. demonstrated that among 32
patientswith ovarian cancer, 34patientswith benignovarian
tumors, and 31 healthy women, CA125 had a sensitivity of
84.4% and a speciﬁcity of 66.3% in predicting this disease
[13]. Serum CA125 levels has also been proposed to reﬂect
therelative volumeoftheovarian tumor,based ontheresults
of previous clinical trials, but this has not been reproducible
across studies [11].
Despite the beneﬁts accompanying the use of CA125,
m a n yc h a l l e n g e se x i s tt h a tr e n d e ri tn o ta se ﬀective in early
screening. One of the primary challenges is its decline in
sensitivity in early-stage ovarian cancer [14]. A number of
false-positive results could also occur, since levels of this
marker are naturally increased with ovulation and may
be elevated with endometriosis, ﬁbroids, and many other
benign conditions; therefore, this marker is more eﬀective
in postmenopausal women. In addition, cutoﬀ levels (30 or
35U/mL) that are used for identifying a positive CA125 test
haveonly beenestablished forpatientswith aclinicalformof
the disease. This value was not recommended for screening
asymptomatic patients [11].
Regardless of these challenges, CA125 has been widely
used as a key screening component of the recent United
Kingdom Collaborative Trial of Ovarian Cancer Screen-
ing (UKCTOS). This large randomized controlled trial isJournal of Oncology 3
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Figure 1: Ovarian cancer tumor markers. Through utilization in screening tests, signals provided prior to clinical diagnosis and symptoms
help determine the value of markers in disease detection as (1) at-risk, (2) early stage, or (3) late stage and diagnostic. Markers investigated
in this paper are categorized according to their marker type.
designed to evaluate the eﬀect of screening on overall mor-
tality. Instead of solely looking at serum levels of CA125, this
trialmakesuseofariskofovariancancer(ROC)algorithmto
eﬀectivelyevaluateovarian cancer risk. Speciﬁcally, the study
lookedatover200,000postmenopausalwomenrandomizing
them to screening (100,000) versus no screening (100,000).
Womenwithin thescreening groupwerefurther randomized
to undergo annual transvaginal ultrasound (TVS) alone
(50,000) or multimodality screening (MMS) with annual
CA125 values interpreted by the ROC. In the ultrasound
screening (USS) group, 845 of 48,230 women underwent
surgery(1.8%)comparedto97of50,078womenintheMMS
group (0.2%). Preliminary results have been promising,
as primary invasive cancers of the ovary and fallopian tube
with the MMS approach have achieved a sensitivity, speci-
ﬁcity, and positive predictive value of 89.5%, 99.8% and
35.1%, respectively. The USS group reported sensitivity,
speciﬁcity, and positive predictive value of 75%, 98.2%, and
2.8%. Interestingly, 48% of invasive malignancies (58) were
diagnosed instageI/II[15].Itwillbeimportant todetermine
the eﬀect of these screening eﬀorts on overall mortality
within the coming years, and if they remain consistent in
detecting the disease in its early stages.
3.1.2. BRCA1/BRCA2. Screening methods that focus on
identifying mutations and abnormalities in BRCA1 and
BRCA2 genes have also been extensively used in current4 Journal of Oncology
clinical practice. With mutations in these tumor suppressor
genes, women have dramatically increased risks in develop-
ingovarian cancer.Byage70,womenwith BRCA1orBRCA2
mutations have been shown to have a 20–60% calculated
risk of ovarian cancer [16]. However, these familial cases
only account for roughly 10% of cases, as ninety percent
of ovarian cancers are sporadic in nature [4]. These genes
have also not been associated with certain ovarian cancer
stagesorhistologicalsubtypes[17].Additionally,womenless
than 70 years of age only have demonstrated a 5% incidence
rate in BRCA1 mutations [16]. While not as eﬃcient as
is currently believed, additional screening tests along with
BRCA1/BRCA2 are needed to accurately detect the presence
of ovarian tumors within patients.
3.1.3. Ultrasonography. Ultrasound, speciﬁcally transvaginal
sonography (TVS), is another screening technique currently
in use with the potential to aide in early detection. Among
25,327 asymptomatic women who received annual TVS
screenings over 18 years, one study found a sensitivity of
85%, 98.7% speciﬁcity, and a positive predictive value of
14% [18]. Supplementary studies have demonstrated similar
elevated speciﬁcity and positive predictive value for ovarian
cancer, noting its promising use in early screening [19, 20].
The high sensitivity noted during early stages of the disease
h a se n c o u r a g e di t su s ea saﬁ r s t - l i n et e s t .
Despite the many beneﬁts that have been demonstrated
through transvaginal ultrasound, multiple limitations pre-
vent widespread use. The foremost limitation involves the
overall cost of performing annual screenings of the entire
postmenopausal population [4]. Additionally, it is felt that
the majority of epithelial ovarian cancer grows rapidly and
metastasizes early in disease [21]. This makes it diﬃcult to
track the progression and location of the tumor.
3.2. Implications of Acceptable Screening Techniques. In order
to overcome these challenges, it is beneﬁcial to distinguish
the various types of ovarian cancer markers. Based on a
s t u d yb yU r b a na n dD r e s c h e r[ 22], ovarian cancer markers
can be diﬀerentiated into three categories. Figure 1 depicts
the behavior of these three theoretical markers through-
out the development of ovarian cancer, from early risk
to cancer formation, late-stage cancer, and ﬁnally clinical
diagnosis. Late-stage tumor markers in Figure 1 are good
diagnostic markers, as they remain elevated around the time
of diagnosis. However, prior to diagnosis, these markers
remain clinically undetectable in the early-stages of the
disease. Useful early stage markers need to detect the disease
when it is still localized. High-risk markers are elevated
in high-risk patients even though there is still no disease
process. Once these target patients are identiﬁed, preventive
treatment, if available, can be implemented early to ensure
thebest possible prognosis. The associated markers that were
investigatedinthispaperarefurthercategorizedaccordingto
their marker type (early stage or late stage) in Figure 1.
3.2.1. Early-Detection Requirements. The low incidence of
ovarian cancer within the postmenopausal population in
Europe and the United States creates many restrictions
which prevent the development of eﬃcient and eﬀective
early screening techniques. Badgwell and Bast proposed that
a useful screening mechanism must achieve a speciﬁcity
larger than 99.6% to obtain a positive predictive value (PPV)
greater than 10%, and a sensitivity greater than 75% [4]. The
feeling among many gynecologic oncologists involved is that
the numbers needed to treat (NNT) is 10 surgeries per case
of ovarian cancer detected [4, 23]. Screening techniques that
f o c u so nt h i sm a yb ei m p o r t a n tt oo v e r c o m et h ec h a l l e n g e s
that accompany the detection of early forms of ovarian
cancer.
Previous and current studies have generally directed
their focus on three methods to identify potential candidate
aﬀected genes within ovarian cancer: (1) downregulated
genetic expression in ovarian cancer, (2) other cancers with
epigenetic alterations in new genes and tumor suppressor
genes which possess epigenetically related genes, and (3)
genes with loss of heterozygosity (LOH) regions [24]. The
focus of few additional studies has been on identifying
hypomethylated genes. Researchers and clinicians also have
been interested in various proteins, cytokines, and other
factors that may be expressed throughout the disease.
Prospective tumor markers within ovarian cancer can be
classiﬁed further asnovelserummarkers andkeygeneticand
epigenetic markers. Some of the most promising markers for
the detection of ovarian cancer are included in this study. A
detailed list of various studies and their ﬁndings regarding
these novel tumor markers can be found in Tables 1 and 2.
4.Novel TumorMarkersinOvarianCancer
4.1. Haptoglobin. As an acute phase reactant protein that
originatesmainly fromtheliver,haptoglobinhasbeenshown
to be expressed in some forms of ovarian cancer within the
ascitic ﬂuid and serum asreported in several studies[62, 63].
Supplemental studies have shown its elevation in inﬂamma-
tion, infections, and in malignant disease such as lung cancer
[64],malignant lymphoma [65], and breast cancer [66]. One
study, which accounted for 66 malignant ovarian tumors,
60 benign ovarian tumors, and 10 normal healthy women,
foundsigniﬁcantly higherlevelsofhaptoglobininearly-stage
disease than among healthy controls. This may indicate its
possible importance in diagnosing early forms of the disease.
However, concentrations of this marker were signiﬁcantly
more elevated during late stages of ovarian cancer than in
healthy controls or benign tumors [25].
Survival rates, outcomes, and treatment response moni-
toring have also beencorrelated with expressed levelsofhap-
toglobin.Signiﬁcantlyhigherlevelsofhaptoglobin havebeen
found in early stages of the disease and have been associated
with poor prognosis [25]. Similarly, haptoglobin levels were
found to decrease along with CA125 during chemotherapy
[26]. However, additional studies need to be conducted to
conﬁrm the exact speciﬁcity and sensitivity of this marker
and its behavior during various stages of ovarian cancer.
4.2. Osteopontin. Another ovarian tumorbiomarker that has
been associated with tumor progression and metastasis isJournal of Oncology 5
Table 1: Characteristics of novel ovarian cancer serum markers across various key studies.
Marker Sample size Sensitivity/Speciﬁcity Stage of ovarian
cancer
Types of ovarian
cancer
Additional
comments Reference
Haptoglobin (1) 66M/60B/10H
(2) 24M/11H
(1) Not provided
(2) Not provided
(1) Late stage
(2) Late stage
(FIGO∗ stage III)
(1) Serous,
mucinous,
endometrioid
(2) Not provided
(1) CRP levels
signiﬁcantly
correlated with
haptoglobin levels
(2) Haptoglobin
levels decreased
following
chemotherapy
(1) [25]
(2) [26]
Osteopontin
(1) 40M (FIGO
stage III)
(2) 32M/34B/30G/
31H
(3) 67M/166B
(1) Not provided
(2) 81.3%/54.7%,
93.8%/87.4%#
(3) 90%/19.6%,
95%/7.6%,
98%/4.9%,
90%/14.8%∧,
95%/14.7%∧,
98%/7.6%∧
(1) Late stage
(2) Late stage
(3) Early and late
stage
(1) Not provided
(2) Serous,
endometrioid
(3) Serous
(1) Poor prognosis$
(1) [27]
(2) [13]
(3) [28]
HE4 (1) 67M/166B
(2) 37M/19B/65H
(1) 90%/77.6%,
95%/72.9%,
98%/64.2%,
90%/80.7%#,
95%/76.4%#,
98%/71.6%#,
90%/46.2%∧,
95%/45.9%∧,
98%/30.8%∧
(2) 80%/96%
(1) Early and late
stage
(2) Not provided
(1) Serous
(2) Serous,
endometrioid
(1) Highest
sensitivity in
detecting stage I
ovarian cancer&
(1) [28]
(2) [29]
Mesothelin (SMRP)
(1) 21M/24H
(2) 52M/43B/220H
(3) 30M/68H
(1) Not provided
(2) 60%/98%
(3) 77%/100%
(1) Late Stage
(2) Early stage and
late stage
(3) Late stage
(1) Not provided
(2) Not provided
(3) Not provided
(2) Greater fraction
of ovarian cancer
detected with CA125
than either marker
alone
(1) [30]
(2) [31]
(3) [32]
B7-H4
(1) 236M/150B/
260H
(2) 326M/43B/32H
(1) 65%#/97%#
(2) Not provided
(1) Early stage
(2) Late stage
(1) Serous,
endometrioid
(2) Serous,
endometrioid,
clear cell
(2) 75% of tumors
were positive for one
or both markers
(w/CA125)
(1) [33]
(2) [34]
Prostasin (1) 12M
(2) 64M/137H
(1) Not provided
(2) 51.4%/94%,
92%#/94%#
(1) Late stage
(2) Early and late
stage
(1) Not provided
(2) Nonmucinous
(2) Sensitivities and
speciﬁcities based on
37 nonmucinous
ovarian cancers
(1) [35]
(2) [36]
Macrophage colony
stimulating factor
(M-CSF)
(1) 69M/80H
(2) 69M/55B/634H
(1) 68%/98%, 90%#
(Sensitivity)
(2) Not provided
(1) Not provided
(2) Late stage
(1) Not provided
(2) No diﬀerence
noted
(1) [37]
(2) [38]
Vascular
endothelial growth
factor (VEGF)
(1) 120M/25B/90H
(2) 101M/34B
(1) 77.1%/87%
(2) 74%/71%,
96%#/39%#
(1) Late stage
(2) Early and late
stage
(1) No diﬀerence
noted
(2) Not provided
(1) Additional data
suggest usefulness as
ap r o g n o s t i cm a r k e r
and for therapy
monitoring
(2) Shown to be
signiﬁcantly
associated with
survival
(1) [39]
(2) [40]
Interleukins (IL-6,
IL-8)
(1) 94M/37B/80H
(2) 44M/37P/45H
(1) 87.5%+/98%+
(2) 84%=/95%=
(1) Early stage
(2) Early stage
(1) Not provided
(2) Not provided
(1) [41]
(2) [42]6 Journal of Oncology
Table 1: Continued.
Marker Sample size Sensitivity/Speciﬁcity Stage of ovarian
cancer
Types of ovarian
cancer
Additional
comments Reference
Eosinophil-derived
neurotoxin and
COOH-osteopontin
fragments
(1) 128M/52B/
188H (1) 72%/93% (1) Early stage
(1) Serous,
mucinous,
endometroid, clear
cell
(1) [43]
OVX1 (1) 204M/77B/
117H
(1) 76%“/Decline in
speciﬁcity (1) Early stage (1) Endometrioid,
mucinous
(1) OVX1 alone
does not increase the
sensitivity to the
combination of
CA-125 and M-CSF
for identifying
patients with
ovarian carcinoma
(1) [44]
Lysophosphatidic
acid (LPA) (1) 117M/27H (1) 91%/96% (1) Early and late
stage (1) Not provided
(1) Statistically
signiﬁcant
diﬀerences between
preoperative and
healthy control
levels, pre- and
postoperative levels
(1) [45]
Apolipoprotein A1
(APOA1) and
transthyretin
(1) 42M/65B/76H (1) 52.4%/96.5% (1) Early stage (1) Serous (1) [46]
M: cases of ovarian cancer, B: benign ovarian tumor, G: other gynecological cancers, P: benign pelvic tumors, H: healthy individuals.
∗Federation of Obstetrics and Gynecology.
$32 patients with signiﬁcant increases in osteopontin.
#When combined with CA125.
∧Benign disease versus stage I ovarian cancer assay sensitivity.
&In comparison to CA125, SMRP, CA72-4, and osteopontin.
+IL-8, anti-IL-8 antibodies, and CA125.
=IL-6, IL-8, epidermal growth factor (EGF), VEGF, monocyte chemoattractant protein-1 (MCP-1), and CA125.
“When combined with CA125II and M-CSF.
osteopontin (OPN). Expressed as an adhesive glycoprotein
and synthesized by vascular endothelial cells and osteoblasts,
OPN regulates immune and inﬂammatory process within
various cell types. This is especially true following infection
or cell injury [27, 67]. Since OPN also has the ability to
inhibit apoptosis, there is a positive correlation between
metastatic potential and increasing OPN expression [67].
Many key studies have demonstrated the usefulness of
this marker with disease monitoring following oophorec-
tomy and in detecting recurrent ovarian cancer [13, 68]. It
also may be used as a noninvasive screening test for early
diagnosis, as elevated levels of OPN can be measured in
the urine [43]. It was shown to be signiﬁcantly elevated
during advanced stages of the disease, when combined with
CA125 in a biomarker screening panel, high sensitivity was
achieved,reaching93.8%,butexhibitinglowspeciﬁcitylevels
of 33.7% [13]. With a sensitivity level of 81.3% alone [13],
OPN may have a lower potential than CA125 to accurately
detect the presence of ovarian cancer. However, patients with
signiﬁcantly higher levels ofOPN were noted to have a much
poorer prognosis [27].
4.3. Human Epididymis Protein 4 (HE4). As a component of
the disulﬁde-core protein group, the WFDC2 (HE4) gene is
also elevated in ovarian cancer [69–71]. In addition, many
institutions have noted its potential as a promising marker
[3]. As exhibited in Table 1,ak e ys t u d yn o t e dt h em a r k e r ’ s
high sensitivity and speciﬁcity in 67 ovarian cancer cases,
reaching levels of 90% and 77.6% [28]. In comparison to
CA125, SMRP, CA72-4, and osteopontin, HE4 possessed
the highest sensitivity in detecting stage I ovarian cancer
[28]. The expression of HE4 is more in endometrioid and
serous ovarian cancer, possibly enabling one to distinguish
among several tumor types [29]. Another reported beneﬁt is
that HE4 has less false positives, especially in nonmalignant
ovarian diseases (more speciﬁc), and possessing a similar
sensitivity as CA125among blinded serumstudies ofwomen
with nonmalignant disease [71, 72]. This demonstrates a
possible role with CA125 in the creation of an eﬀective
biomarker panel.
HE4’s role in a prospective biomarker panel for early
screening has been widely studied. The most notable role
of HE4 thus far is identifying cancers preoperatively using
CA125andHE4with94%sensitivity. Theutilityofscreening
is not well tested, and adding HE4 to CA125 for followup
of previously treated ovarian cancer cases shows minimal
(and not likely clinically useful) changes in sensitivity 72.9%
versus 76.4% [28].Journal of Oncology 7
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4.4. Mesothelin. Normally expressed on the surface of
mesothelial cells lining the body cavities as the name
suggests, mesothelin is a protein that has shown to be
a helpful diagnostic marker of several cancers such as
mesotheliomas, ovarian, and pancreatic cancers, where it is
overexpressed [30]. This marker has very high speciﬁcity as
well as sensitivity for patients with ovarian cancer [29].
Mesothelin has many beneﬁcial characteristics that set it
apart from other potential markers currently being studied.
Its preeminent distinctiveness focuses on its temporal stabil-
ity [73], which may assist in earlier diagnosis of high risk
patients [71]. Additionally, when combined with CA125 as a
combined marker, McIntosh et al. noted a greater sensitivity
for cancer diagnosis. Mesothelin was also shown to possess
comparable speciﬁcity and sensitivity to CA125 for ovarian
cancer diagnosis [31]. This suggestsa potential supplemental
role in combination with CA125 in the monitoring and
diagnosis of patients with ovarian cancer. Another beneﬁt of
this marker is thatit is released into the urine, oﬀering a new,
noninvasive approach to the detection of ovarian carcinoma
[71].
4.5. B7-H4. Shown to promote malignant transformation of
epithelialcells,B7-H4isexpressed inTcellsaswellasovarian
carcinoma [73, 74]. This immunomodulatory protein has
also been shown within serous, endometrioid, and clear cell
ovarian carcinomas [34]. Appreciably,at 97% speciﬁcity, B7-
H4 levels were found to be elevated within 45% of early-
stage cancers [33]. Most notably, a larger portion of ovarian
cancers were detected when combined with CA125 (65%)
than either B7-H4 (45%) or CA125 (52%) individually.
4.6. Prostasin. Prostasin, generally secreted by the prostate
gland as a serine protease, has been shown to be overex-
pressed in ovarian cancer cell lines [36]. Mok and coinves-
tigators discovered that this marker was strongly expressed
within cancerous epithelial tissue in comparison to the
normal ovary. Among 37 nonmucinous ovarian tumors and
in combination with CA125, prostasin showed encouraging
results in a biomarker panel. Sensitivity and speciﬁcity of
92% and 94% were noted in detection of ovarian cancer
[36]. Further clarity of early-stage sensitivity still needs to be
achieved.
4.7. Macrophage Colony Stimulating Factor and OVX1. As a
cytokine that stimulates the diﬀerentiation and growth of
macrophages and monocytes, macrophage colony stimulat-
ing factor (M-CSF) has been discovered to have elevated
levels in ovarian cancer patients [75]. At 98% speciﬁcity, this
marker was measured in 68% of ovarian cancer cases [37].
When combined with CA125, the prospective biomarker
panel demonstrated sensitivity around 90% [37].
Promising studies have also included the use of OVX1
with M-CSF. OVX1, a modiﬁed Lewis X determinant on
mucin, is signiﬁcantly increased in epithelial ovarian cancer,
as 70% of 93 patients had elevated levels with clinically
proven disease [76]. In spite of loss in speciﬁcity, when com-
bined with M-CSF and CA125II, sensitivity levels improved
to 76% in comparison to the sensitivity of CA125II alone
(66%) [44].
4.8. Vascular Endothelial Growth Factor (VEGF). Shown
to play an integral role in ovarian cancer pathogenesis
[77], VEGF has been reported in both nonmalignant and
metastatic forms of this disease [78]. Patients with stage I
ovarian cancer demonstrated signiﬁcantly elevated levels of
VEGF when compared with benign ovarian disease. They
also possessed high sensitivity values (96%),when combined
with CA125, but low speciﬁcity [39]. In addition, VEGF
levels were signiﬁcantly elevated in advanced stages [41].
O t h e rd a t aa l s os u g g e s t e di t su s e f u l n e s sa sap r o g n o s t i c
marker and for therapy monitoring. Postoperative VEGF
levels were signiﬁcantly lower in comparison to preoperative
levels,whilesigniﬁcantlyelevatedvalueswereseeninpatients
with metastasis as compared to patients lacking metastasis
[39]. This may be compared clinically in the near future
as the latest randomized trial for advanced stage ovarian
cancer in the US, incorporating anti-VEGF therapy with
standard cytotoxic agents. Since speciﬁcity remained low
within biomarker panels from the addition of this marker,
VEGF may serve a better role as a prognostic marker in
women with the disease. More research is needed to further
deﬁne its role.
4.9. Additional SerumMarkers. Validation ofotherbiomark-
ershasprovendiﬃcult,eventhoughresearchers havederived
many promising results. Markers such as interleukins 6
and 8, lysophosphatidic acid, eosinophil-derived neurotoxin
and COOH-osteopontin fragments, apolipoprotein A1, and
transthyretin have mostly noted large increases in sensitivity
and speciﬁcity in several forms of ovarian cancer [41, 46, 79,
80]. Many additional studies are required to truly determine
their eﬀectiveness in early detection.
5.Key Geneticand EpigeneticMarkers
5.1. Hypermethylated/LOH Genes
5.1.1. BRCA1. As mentioned previously, the BRCA1 gene
has been extensively studied due to its inherent role in
familial ovarian and breast cancers. It is responsible for
the preservation of genomic integrity and located on
chromosome 17q12-21 [81]. Various studies have noted
immense amounts of hypermethylation of this gene among
ovarian tumors [82]. Hypermethylated BRCA1 gene has
diminished expression values, ranging from 12% to 16%
amongepithelialovarian cancers[17,47].Apromising factis
that BRCA1 silencing has been discovered within early-stage
disease, including some stage IA [17]. Even though common
acceptance of BRCA1 mutations has been through familial
linkage, LOH has been shown to occur in a vast amount of
sporadic forms of the disease [81, 83]. Additionally, LOH of
BRCA1 has been correlated with hypermethylation in this
cancer[81].Therefore,BRCA1mutationsmayplayakeyrole
in both sporadic and familial forms. However, as this gene is
hypermethylated within only a fraction of ovarian cancers,10 Journal of Oncology
a number of additional tumor suppressor genes and other
genes are needed to eﬀectively detect all forms of the disease.
Recent studies with BRCA1, however, have noted a
promising role in determining clinical outcome for ovar-
ian cancer patients. Hypermethylation of BRCA1 strongly
associates with the loss of BRCA1 protein and RNA [84].
This is signiﬁcantly associated with a poor patient outcome
[47]. These studies help demonstrate that BRCA1 hyperme-
thylation may prove as a minimally invasive approach for
predicting patient response to standard therapies, especially
since it has been found within ovarian cancer patient serum
[53].
5.1.2. Ras Homologue Member 1 (ARHI). Located on chro-
mosome 1p31, this tumor suppressor gene has shown LOH
in roughly 40% of ovarian carcinoma [48, 85]. Normally,
ARHI is expressed in consistent amounts within normal
ovarian epithelial cells. This expression is mainly lost upon
the formation of ovarian cancer [48]. Interestingly, the
parental allele that remains is silenced in 10–15% of patients
with the disease [86, 87]. ARHI has also been signiﬁcantly
associated with serous and endometrioid forms as well as a
prolonged disease-free outcome, despite having no correla-
tion with any stage or grade of the tumor [88]. However,
supplementary studies are required to truly conﬁrm this
characteristic.
5.1.3. OPCML. Demonstrated to be hypermethylated or
haveLOH in 27–49%ofovarian cancercases, opioidbinding
protein/cell adhesion molecule-like gene (OPCML) is shown
to reside at chromosome 11q25 [49]. One study found a
signiﬁcant amount of methylated OPCML in early stages of
the disease. However, tumor grade, stage, and histological
type had no inﬂuence on the presence of methylation [89].
Due to small sample sizes and lack of many large studies
in this area, more research is needed to correlate expression
level of this gene with ovarian cancer.
5.1.4. RASSF1A. Not only has RAS association domain
family 1A gene (RASSF1A), a tumor suppressor gene, been
identiﬁed in ovarian cancer, but also in lung, renal cell,
colon, and breast cancers [90]. Located at chromosome
3p21, Yoon et al. found methylation rates of this gene as
high as 40%. This characteristic is signiﬁcant, as normal
tissue samples did not show gene methylation [90]. Its
usefulness in a biomarker panel was demonstrated when
combinedwith BRCA1.Hypermethylation improved to 68%
and was seen across all histological types, grades, and stages
that were examined [53]. Due to its usefulness in a small
genetic marker panel, further studies should be looked at
to determine its true eﬀectiveness with other markers (i.e.,
CA125) in detecting ovarian carcinoma.
5.1.5. Insulin-Like Growth Factor Binding Protein 3 (IGFBP-
3). Asone of the most abundant IGF binding proteinsnoted
in the serum, IGFBP-3 is typically shown to regulate the
apoptosis and mitogenesis suppression properties of IGF
proteins [54, 91]. Studies have shown detection of IGFBP-
3 promoter methylation in 44% of epithelial ovarian cancer
cases[54].Patientswiththisformofovariancancerhavealso
displayed lower serum levels of this protein in comparison
to healthy individuals [92]. Signiﬁcantly higher levels of
methylation were noted in early-stage disease and associated
w i t ho v e r a l ls u r v i v a lo u t c o m e[ 54]. It remains unknown if
thismarkercouldbeusedasaprognosticmarkerinlate-stage
patients.
5.1.6. 14-3-3sigma (SFN). A key characteristic that has
distinguished SFNisitsabilitytocharacterize thehistological
forms among various types of epithelial ovarian cancer.
Among many ovarian cancercelllinesthatwere composedof
diﬀerent histological forms (clear cell, serous, endometrioid,
and mucinous), Kaneuchi et al. discovered higher frequen-
cies of methylation (78.6%) among clear cell ovarian tumors
when compared to other histologic subtypes of epithelial
tumors. Lower expressions of this protein were demon-
strated, suggesting 14-3-3sigma gene inactivation through
methylation. Protein expression was dramatically elevated in
other histological types (89.5% serous, 90% endometrioid,
and 81.8% mucinous) as methylation rates widely diﬀered
among each form [55]. One limitation could be 14-3-3sigma
expression being elevated among both normal controls and
73.5% of ovarian cancer cases [93]. While certain treatment
regimens may be more eﬀective with the knowledge of the
histological type of ovarian tumor, the presence of ovarian
cancer will need to be conﬁrmed through the use of other
markers or screening techniques prior to this marker’s use.
5.2. Hypomethylated Genes
5.2.1. Metastasis-Related Gene Synuclein Gamma (SNCG).
Found on chromosome 10 and not expressed in normal
ovarian epithelial tissue, SNCG has been generally expressed
in advanced and aggressive ovarian cancer [50, 86]. Also
expressed in breast cancer and thought to have a similar role
in ovarian cancer, SNCG causes signiﬁcant cellular prolifera-
tionanddiﬀerentiation[50].Studies,however,havevariedin
thedegreeofhypomethylationfound,rangingfrom75.7%to
100% [50, 51]. To our knowledge, no additional correlation
has been made relating to the clinical stage or histological
tumor type and promoter SNCG hypomethylation. More
extreme studies are needed to prove the exact worth of this
marker.
5.2.2. Satellite 2 DNA (Sat2): Chromosome 1 (Chr1), Satellite
Alpha (Satα). More prevalent in high grade and advanced
stage tumors, Sat2 DNA has shown high degrees of
hypomethylation among adjacent heterochromatin regions
of chromosome 1 in ovarian cancer [94]. Hypomethylation
levels reached 30% (Chr1, Sat2) and 33% (Chr1 Satα)a m i d
115ovarian cancerspecimens [52].Serousandendometrioid
ovarian tumor forms could be distinguished with elevated
hypomethylation levels than other histological types [52].
Interestingly,aconnectionbetweentumorstageanddiﬀerent
Sat2 DNA hypermethylation has been reported [94].Journal of Oncology 11
5.2.3. DNAJ (MCJ). The MCJ gene, DNA methylated and
silenced within normal cells, may be regarded as a useful
marker in chemotherapy treatment response monitoring
among ovarian cancer patients. This gene (mapped to
chromosome 13q14.1), when expressed in ovarian cancers,
has been identiﬁed to render epithelial cells to become more
sensitive in response to many mainstream chemotherapeutic
agents (i.e., paclitaxel and cisplatin) [56, 95]. Among high
levelsofmethylation (>90%)in 17% of ovarian cancer cases,
Strathdee and his colleaguesassociated a poorer survival rate
and response to chemotherapy [56]. These high levels of
methylation have been linked to the lack of expression of the
MCJ gene [95]. While the prognostic value of this marker
remains high, more studies are required to characterize the
chemosensitivity correlation.
5.2.4. p53. Involved in cell cycle regulation, p53 is regarded
as one of the most widely studied tumor suppressor genes.
Mutations in this gene have been shown in 50% of ovarian
carcinomas [16]. Beneﬁts of the p53 marker use include
measuring metastaticpotential[96]anddistinguishing high-
grade serous histological ovarian tumors from other ovarian
cancer types [97]. Since allele loss and mutations have been
demonstrated across all stages of ovarian tumors [97], it
may prove eﬀective in earlier detection of this disease. As
only 50% of mutations within this gene occur in ovarian
cancerpatients,thismaystillcontinuetobethekeybarrierin
widespread use of this marker for ovarian cancer detection.
5.2.5. ARID1a. ARID1a, a key epigenetic regulatory gene,
recently has drawn large interest due to its demonstrated
involvement in both clear cell and endometrioid ovarian
cancers. Published in September 2010, two crucial studies
showed that mutations in the ARID1awere found inroughly
half of clear cell ovarian cancers tested. Wiegand et al. stated
that ARID1a mutations were seen in 55 of 119 ovarian clear
cell carcinomas (46%), in addition to 10 of 33 endometrioid
carcinomas (30%) [58]. ARID1a mutations were also found
in 24 of 42 clear cell ovarian carcinomas tested (57%)
[59]. From these discovered mutations, both studies have
suggested ARID1a serving a role as a tumor suppressor gene
with a focus on remodeling chromatin via unwinding DNA
[58, 59]. When this gene is unable to function properly, it
may lead to cancer formation.
Despite these fascinating results, it will be interesting
to view if these two forms of ovarian cancer continue to
show mutations in this gene. More studies should be done to
identify this defect in these ovarian cancer forms, determin-
ing its use as an eﬀective detection marker. Studies should
also focus on the epigenomes of these two cancer forms,
noting any diﬀerences that may occur despite mutations in
theARID1agene.Assuggestedbyoneresearcher, byhavinga
better understanding of the epigenomes of these two ovarian
cancer forms, it may lead to better epigenetic therapy in the
future [98].
6.Proteomicsand Metabolomics
Several of the potential ovarian cancer tumor markers have
been identiﬁed due to the new technologies and techniques
that have been derived through the ﬁelds of proteomics and
metabonics. Their importance lies in the pathophysiology of
cancer, as thegenetic defect is transcribed and translated into
proteins, ultimately leading to the abnormal phenotype [99].
These ﬁelds have ushered in new promises, ranging from the
discovery of ovarian cancer in its early stages to treatment
modality monitoring and guidance.
Techniques in these ﬁelds have focused on ﬂuid and
tissue screening. In these screenings, focus is drawn on
identifying the presence of disease, or characterizing known
malignant cancer samples [100]. The traditional approach
utilizes mass spectroscopy (MS) to evaluate serum samples
for diagnostic markers. New technological approaches have
expanded techniques to include liquid chromatography,
matrix-assisted laser desorption and ionization, and surface-
enhanced laser desorption and ionization to screen serum,
urine, and ascites for potential markers of early ovarian
cancer [100]. Through these screenings, detection of disease
recurrence may also have a correlation with the presence of
certain markers.
Unfortunately, several issues have been raised utilizing
these methods to help determine potential biomarkers.
Studies have shown that protein concentrations where
potential markers may exist for early detection are 106-107
less than that of plasma proteins [101]. Further attempts
thatare designed todecrease plasma concentrations mayalso
decrease potential markers that are bound to albumin [102].
However, several researchers have reported high sensitivities
and speciﬁcities for potential markers using traditional MS
practices between healthy and cancer-ridden serum samples
[103, 104]. It will be interesting to see how these techniques
translate to predicting the presence of ovarian cancer in
patients.
As discussed previously, several potential tumor markers
have been investigated in several ovarian cancer forms. Most
ofthesemarkersthatwereconﬁrmedandvalidatedinfurther
studies were classiﬁed into plasma proteins (apolipopro-
tein) and acute phase reactant proteins (transthyretin, hap-
toglobin, etc.) [105]. Unfortunately, these markers have been
present in a variety of diseases and conditions, decreasing
their speciﬁcity and desirability as potential biomarkers for
ovarian cancer.
Clinically, trials are currently underway to identify
proteomic patterns that can diagnose patients with ovarian
carcinoma. A Gynecologic Oncology Group Trial (GOG-
220) of over 2,000 women has this goal. This study will
look at serum samples of women with an undiagnosed
pelvic mass who are undergoing surgical intervention [100].
Goals of this study include identifying proteomic patterns
that can diﬀerentiate between benign or nonovarian malig-
nancies and malignant ovarian cancer in presurgical serum
collections. Other goals consist of utilizing these patterns
to distinguish between early- and late-stage disease and
determiningdisease prognosis[100].Resultsofthistrialhave
notyetbeenreported.Largerclinicaltrialswithlargersample12 Journal of Oncology
sizesaretrulyneededbothforthediscoveryandvalidationof
potential markers and patterns for ovarian cancer detection.
This may help reduce false positive rates and help hone in on
predicative diagnostic markers that can apply to many forms
of the disease.
7.BiomarkerPanelsinDetectionof
OvarianCancer
Many promising predictive tumor markers have been eval-
uated in patients with ovarian cancer. These markers have
been evaluated in combination with one another to improve
the sensitivity, speciﬁcity, and positive predictive value of
the test, as 20% of ovarian cancers have been noted to
express little or no amounts of CA125 [106]. One key panel
focuses on combinations of nine markers, including CA125,
SMRP, HE4, CA72-4, activin, inhibin, osteoponin, EGFR,
and ERBB2 among 233 women who had ovarian cancer.
Results from this study showed that the combined markers
of CA125 and HE4 had a greater sensitivity than either
marker alone [28]. Another panel of six tumor markers
also improved the sensitivity and speciﬁcity of CA125 alone
(72%, 95%) to 95.3% and 98.7%. In one study, 221 of 224
women in a test group that included 43 women with ovarian
cancer were classiﬁed appropriately (98.7%) [107].
Data from another study with a four-marker panel
(CA125, apolipoprotein A-1, transthyretin, and transferrin)
reportedasensitivity andspeciﬁcityof96%and98%,respec-
tively, for early-stage ovarian cancer [108]. Additionally,
another panel test showed ovarian cancer sensitivity and
speciﬁcity of91.3% and 88.5% [109]. These panels, however,
have yet to be validated in clinical trials.
Whilespeciﬁcityhasshown tolackintermsofsinglegene
methylation assessment, a common belief is that suﬃcient
accuracy may be achieved for population screening through
the use of multiple methylation markers [110]. Several stud-
ies have supported this belief. Detection of ovarian cancer
in high-risk patients was signiﬁcantly predicted through the
use of a methylated ﬁve-gene panel [111]. Progression-free
survival of ovarian cancer was associated with one panel
consistingofover100methylated DNAmarkers[112].While
these markers may assist CA125 in improving the overall
speciﬁcity of ovarian cancer detection, more studies are
neededtoconﬁrmthisfact.Furtherinvestigationisneededto
evaluate the total worth of marker panels as a screening and
detectionmodality beforeimplantationintoclinicalpractice.
8.FDA-ApprovedScreeningTests
(CA125,HE4,andOVA1)
Some of the key screening tools that are utilized in current
practice involve identifying elevations of markers such as
CA125 and HE4, as discussed previously. These tools are
frequently used either in combination with each other, or
even with the application of transvaginal ultrasound for
detection of ovarian disease.
One of the newest serum-based tests (approved in
2009) is the OVA1 test. The key purpose of this test was
to identify ovarian cancer risk in women who presented
with an adnexal mass and were planning surgery. Five
signiﬁcant proteins were measured in the serum (CA 125-
II, transthyretin, apolipoprotein A1, beta 2 microglobulin,
and transferrin) and combined with an algorithm to yield
an overall OVA1 score [113]. This score diﬀered depending
on menopausal status, diﬀerentiating patients either into
a low- or high-risk group. Among 516 eligible women in
the initial trial, OVA1 was found to aide in the presurgical
assessment of patients. Sensitivity improved from 72.2%
to 91.7% for nongynecologic oncologists and from 77.5%
to 98.9% for gynecologic oncologists. Negative predictive
values were 93.2% for nongynecologic oncologists, and
97.6% for gynecologic oncologists [114]. Overall, OVA1 was
shown to have detected the majority of ovarian cancers that
were missed by preoperative assessment alone. Currently,
publication of this trial is still pending.
OVA1 has not yet been tested in screening patients for
early-stage ovarian cancer. On the surface, it looks very
similar to other biomarker panels that have been already
studied. Even though this panel focused on women who
presented with adnexal masses, a correlation in the panel’s
applicability should not yet be drawn to women who present
with no masses until studied further. As suggested by one
physician, consumer pressure will most likely occur to use
it as a screening tool. This may lead to more expensive
interventions and greater amounts of false-positive results
[114].
The OVA1 panel also has shown some limitations,
discouraging its use as a potential screening modality.
Assay interference has occurred in triglyceride levels greater
than 4.5g/L and rheumatoid factor levels of at least 250
international units/mL. The cost alone has been high, valued
at roughly $650 per patient [114]. Larger studies showing
high predictive values are needed to justify this cost prior to
its use in clinical practice as a screening tool.
Currently, many centers oﬀer ovarian cancer screening
through CA125 measurements and annual transvaginal
ultrasound. Unfortunately, many eﬃcacy studies have been
conﬂicting, and recent studies have demonstrated ovarian
cancer screening less eﬀective, even in high-risk populations
[115, 116]. One large cohort study even noted when com-
bining both screening modalities among 341 asymptomatic
women, that sensitivity and speciﬁcity were only 66.7%
and 82.9%, respectively. No cancers were detected at ﬁrst
screening episodes.Inaddition,amongfourwomenwhohad
ovarian cancer, each had a normal screening episode prior
to diagnosis [117]. Based on this and other studies, only
utilizing these two modalities for ovarian cancer screening
mayproveineﬀectivewithahigh rateoffalse-negative results
and poor sensitivity.
As with all FDA-approved screening tests, more clinical
studies are needed to determine their true predictive values
in the early detection of ovarian carcinoma. While each one
of these approvedtests haveshown some beneﬁt,they should
never be used by themselves in place of clinical judgment.
Clinical evaluations including risk assessment should be
combined with additional screening tests (i.e., biomarker
panels and transvaginal ultrasound) to ensure the greatestJournal of Oncology 13
sensitivity and speciﬁcity possible. Supplemental research
should also center on combinations of these tests and their
predictive values, helping providers better understand the
most eﬀective method for ovarian cancer detection.
9.FutureImplications,Direction,
and Improvements
New and innovative approaches will still be needed to
detect preclinical disease. Biomarkers continue to have great
potential in serving as an eﬃcient screening tool in the
early detectionofovarian cancer. However,mismanagement,
overuse,and rising costsofcertainscreening techniqueshave
created many problems in eﬀectively detecting early forms of
this disease. These tests have often lacked cost eﬀectiveness,
as many women who develop ovarian cancer lack signiﬁcant
risk factors. This leads to a need for screening of all
asymptomatic women for the testing to be eﬀective. In order
to perfect and establish an eﬃcient widespread screening
modality within the general public, further reﬁnements need
to be made among the screening tests through randomized
controlled trials. More resources and tests should also be
sought, while screening all women who may be at high risk
for developing ovarian cancer.
Some authors have suggested implementing risk calcu-
lations to determine the eﬃcient allocation of screening
resources [11]. These calculations are based on the baseline
CA125, the patient’s age upon tumor development, CA125
elevation rate following tumor development, and expected
variation in CA125levels.Ideally, CA125would be measured
annually, since ovarian cancer commonly presents as a
rapidly growing tumor. By observing trends over time of
CA125,womenwith stable levelscanberuledout,increasing
the overall speciﬁcity. When putting these principles into
practice in 22,000 postmenopausal UK women over the age
of 45, Skates et al. demonstrated a high level of speciﬁcity,
while increasing early detection sensitivity to 86% from
70% [11]. Newer data among 202,638 postmenopausal
UK women between ages 50 and 74 showed similar high
levels of speciﬁcity and sensitivity: 98.2–99.8% and 84.9–
89.4%, respectively [15]. While reﬁnement and testing
of this approach is still needed within large-scale trials,
a combination of many biomarkers and early screening
modalities may be the key to obtain the most accurate forms
of ovarian cancer detection.
In terms of clinical setting, practical screening tech-
niques need to focus on biomarkers that demonstrate
temporal stability and are relatively noninvasive to obtain.
Approaches and tests that look at markers found in the urine
(mesothelin) or serum may help identify more clinically
relevant markers. This would help reduce the need to obtain
tissue samples from normal and ovarian cancer patients for
detection of this disease. Similarly, markers that show long-
term stability may aid in determining risk and ultimately
improve the overall sensitivity and speciﬁcity of ovarian
cancer detection.
Identifying early forms of ovarian carcinoma and a
patient’s prognosis may have a greater chance of being det-
ected through the combination of many biomarkers that
should be studied further. Among the promising markers
investigated, HE4 and mesothelin are some of the best
markers thathaveenhanced theuse ofCA125duetothehigh
sensitivity and speciﬁcity of these combination panels [28].
Additionally,panelswhich includedtheMCJgeneandVEGF,
both shown to be related to prognosis, may accurately detect
patient survival outcome. Ultimately, the goal will be to
determine the behavior of complementary markers with key
markers to help improve the sensitivity as well as maintain
the speciﬁcity of detecting early-stage ovarian cancer and
determining disease prognosis.
10.ConclusionsandEmerging Trendsin
BiomarkersforOvarianCancer
The ultimate aim of eﬀectivescreening techniques is to bring
about a reduction in mortality from ovarian cancer. As early
detection continues to be vital in ovarian cancer patients,
biomarkersmayholdthekeytounlockingeﬀectivescreening
strategies for the general population. It is also important to
identifyscreeningtechniqueswithlowfalsepositiveratesand
high positive predictive value, so that the number ofnegative
surgical interventions can be minimized. Since our currently
a v a i l a b l es i n g l em a r k e r sa r en o th i g h l ys e n s i t i v eo rs p e c i ﬁ c ,
a combination of markers may be utilized as a proﬁle for
risk assessment. The current problem with screening panels
is that the improvement in sensitivity usually correlates
with a decrease in speciﬁcity, making the target positive
predictive value hard to obtain. The multimodal screening
proﬁles of the genetic markers could be utilized in the
future for risk assessment, early diagnosis, prognosis, and
response to therapeutic treatment. Recent literature reports
state that the screening is only recommended for the high-
riskpopulationidentiﬁedasthosewithafamilyhistoryofthe
disease, women with BRCA1 and BRCA2 mutations, or with
hereditary nonpolyposis colorectal cancer. Recent literature
reports also emphasize that the diﬀerent subtypes of ovarian
cancer may have diﬀerent genetic biomarker expression
proﬁles. Current randomized controlled screening trials are
directed towards ﬁnding the best molecular and genetic
markers for the speciﬁc histology of the ovarian tumor with
the most impact on reduction in morbidity and mortality.
The tumor markers identiﬁed in these trials may also lead to
novel targets for antitumor therapy.
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